Company profile for Exciva

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Exciva is a clinical-stage biopharmaceutical company focused on innovative symptomatic treatments for Alzheimer’s disease dementia. Its lead program, the SERENADA Phase 2/3 study, evaluates a novel therapy for agitation in Alzheimer’s patients. The lead project builds on two innovative development approaches emerging from decades of preclinical and clinical research in Alzheimer’s disease. Exciva’s candidate combines d...
Exciva is a clinical-stage biopharmaceutical company focused on innovative symptomatic treatments for Alzheimer’s disease dementia. Its lead program, the SERENADA Phase 2/3 study, evaluates a novel therapy for agitation in Alzheimer’s patients. The lead project builds on two innovative development approaches emerging from decades of preclinical and clinical research in Alzheimer’s disease. Exciva’s candidate combines dextromethorphan, an NMDA receptor channel blocker, with EXV-801, a triple-acting agent functioning as a CYP2D6 inhibitor and 5-HT2A/2C receptor inverse agonist.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Hauptstraße 25, 69117 Heidelberg
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-04-28/exciva-doses-first-patient-in-phase-23-trial-of-deraphan-for-agitation-in-alzheimer-s-disease-and-e

PHARMIWEB
28 Apr 2026

https://www.prnewswire.com/news-releases/eqt-life-sciences-co-leads-eur-51-million-series-b-in-exciva-to-advance-its-alzheimers-therapy-into-clinical-phase-2-302665138.html

PR NEWSWIRE
20 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty